I watch the PPS in Tel Aviv will for the story. As I recall, when CANF released data on 2 studies in Dec. 2013, the shares on the Israeli exchanged tanked about 17% before the US markets opened....and just before the company PR'ed the negative results for their dry eye clinical study. The company has some leaky seals, and as usual, those of us on the outside were left holding the bag.
Riding free shares here through the PR release from a $2.34 entry.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.